

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Breast cancer	HER2 (ERBB2; neu); integrin β_1 (CD29)	<p>A study in mice suggests that inhibiting CD29 could help treat breast cancer. In a mouse model of Erbb2-driven breast cancer, Cd29 deficiency in only mammary epithelial tissue significantly delayed tumor induction compared with normal Cd29 expression ($p=0.0004$). In the same mouse model, loss of Cd29 also resulted in lower tumor volumes and less lung metastasis than expression of Cd29. Next steps include studying the molecular mechanism by which CD29 mediates cross talk between ERBB2 and epidermal growth factor receptor (EGFR) and how that could impact the sensitivity of tumors to small molecule inhibitors directed against EGFR.</p> <p>SciBX 3(33); doi:10.1038/scibx.2010.1005 Published online Aug. 26, 2010</p>	Unpatented; licensing status not applicable	<p>Huck, L. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Aug. 16, 2010; doi:10.1073/pnas.1003034107</p> <p>Contact: William J. Muller, McGill University, Montreal, Quebec, Canada e-mail: william.muller@mcgill.ca</p>